Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

60.20USD
13 Dec 2017
Change (% chg)

$1.25 (+2.12%)
Prev Close
$58.95
Open
$58.75
Day's High
$60.50
Day's Low
$58.75
Volume
66,246
Avg. Vol
172,351
52-wk High
$66.55
52-wk Low
$35.50

Chart for

About

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02%... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $2,209.62
Shares Outstanding(Mil.): 36.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage:

Dec 04 2017

BRIEF-Aerie Pharmaceuticals announces appointment Of Nhi Ong director of analytics

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF NHI ONG AS DIRECTOR OF ANALYTICS Source text for Eikon: Further company coverage:

Nov 27 2017

BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial

* Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan

Nov 16 2017

BRIEF-Aerie Pharmaceuticals Q3 loss per share $0.89

* Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update

Nov 08 2017

BRIEF-Aerie Pharmaceuticals appoints John Maltman as vice president of medical affairs

* Aerie Pharmaceuticals announces appointment of John Maltman, PH.D., as vice president of medical affairs Source text for Eikon: Further company coverage:

Oct 30 2017

BRIEF-Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa

* Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa (netarsudil ophthalmic solution) 0.02%

Oct 13 2017

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

Oct 13 2017

UPDATE 1-U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Oct 13 Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

Oct 13 2017

Aerie's glaucoma drug Rhopressa wins backing from U.S. FDA panel

Oct 13 The benefit of Aerie Pharmaceuticals Inc's experimental glaucoma treatment outweighs the risks and the drug should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Friday.

Oct 13 2017

BRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa

* Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​ Source text for Eikon: Further company coverage:

Oct 13 2017

Competitors

Earnings vs. Estimates